PMID- 27882706
OWN - NLM
STAT- MEDLINE
DCOM- 20180312
LR  - 20180417
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 18
IP  - 7
DP  - 2017 Aug
TI  - High frequency of potential interactions between direct-acting antivirals and 
      concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical 
      practice.
PG  - 445-451
LID - 10.1111/hiv.12471 [doi]
AB  - OBJECTIVES: The aim of the study was to analyse the frequency and degree of 
      potential drug-drug interactions (DDIs) between direct-acting antivirals (DAAs) 
      and concomitant medication used by HIV/hepatitis C virus (HCV)-coinfected 
      patients, including antiretroviral therapy (ART) and other drugs. METHODS: All 
      patients with HIV infection and viraemic HCV genotype 1, 3 or 4 coinfection 
      attending a tertiary care centre in Spain (November 2014 to November 2015) were 
      included in the study. DDIs were classified as major, i.e. drugs should not be 
      co-administered, or minor, i.e. close monitoring, dosage alteration or change in 
      timing may be required if drugs are co-administered, following the 
      http://www.hep-druginteractions.org database recommendations. RESULTS: A total of 
      244 patients were included in the study, of whom 224 (92%) were previous 
      injecting drug users. Major DDIs were found for: paritaprevir-r/ombitasvir plus 
      dasabuvir (3D), in 60 (44%) of 138 individuals with genotype 1; 
      paritaprevir-r/ombitasvir (2D), in 22 (37%) of 60 individuals with genotype 4; 
      sofosbuvir/ledipasvir (SOF/LDV), in four (2%) of 198 patients with genotype 1 or 
      4; simeprevir (SMV) plus SOF, in 160 (81%) of 198 patients with genotype 1 or 4; 
      daclatasvir (DCV) plus SOF, in seven (3%) of 244 patients with genotype 1, 3 or 4 
      (P < 0.001). Minor DDIs were found for: 3D, in 123 (89%) individuals with 
      genotype 1; 2D, in 52 (87%) individuals with genotype 4; SOF/LDV, in 154 (78%) 
      patients with genotype 1 or 4; SMV plus SOF, in 129 (65%) patients with genotype 
      1 or 4; DCV plus SOF, in 149 (61%) patients with genotype 1, 3 or 4 (P < 0.001). 
      CONCLUSIONS: Drug-drug interactions between DAAs and ART or other commonly 
      prescribed medications are frequently found among HIV/HCV-coinfected patients. 
      Potential major and minor DDIs are more frequent with 3D, 2D and SMV plus SOF 
      regimens.
CI  - (c) 2016 British HIV Association.
FAU - Macias, J
AU  - Macias J
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
AD  - Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.
FAU - Monge, P
AU  - Monge P
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
FAU - Mancebo, M
AU  - Mancebo M
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
FAU - Merchante, N
AU  - Merchante N
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
AD  - Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.
FAU - Neukam, K
AU  - Neukam K
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
AD  - Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.
FAU - Real, L M
AU  - Real LM
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
AD  - Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain.
FAU - Pineda, J A
AU  - Pineda JA
AD  - Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, 
      Seville, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161124
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/*therapeutic use
MH  - Coinfection/*drug therapy
MH  - Cross-Sectional Studies
MH  - *Drug Interactions
MH  - Female
MH  - HIV Infections/*complications/*drug therapy
MH  - Hepatitis C, Chronic/*complications/*drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Spain
MH  - Tertiary Care Centers
OTO - NOTNLM
OT  - antiretroviral therapy
OT  - common medications
OT  - daclatasvir
OT  - direct acting antiviral agents against HCV
OT  - drug-drug interactions
OT  - ledipasvir
OT  - paritaprevir/r/ombitasvir +/- ombitasvir
OT  - simeprevir
OT  - sofosbuvir
EDAT- 2016/11/25 06:00
MHDA- 2018/03/13 06:00
CRDT- 2016/11/25 06:00
PHST- 2016/09/17 00:00 [accepted]
PHST- 2016/11/25 06:00 [pubmed]
PHST- 2018/03/13 06:00 [medline]
PHST- 2016/11/25 06:00 [entrez]
AID - 10.1111/hiv.12471 [doi]
PST - ppublish
SO  - HIV Med. 2017 Aug;18(7):445-451. doi: 10.1111/hiv.12471. Epub 2016 Nov 24.